HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer

Abstract
No abstract available
Funding Information
  • National Health and Medical Research Council of Australia (631701, 535903, 427601)
  • American Association for Cancer Research
  • Landon Foundation
  • Susan Wojcicki and Dennis Tropper NIH (CA62924)
  • NIH (5R01CA150190-07, P50 CA102701, U01 CA224145)
  • NHMRC (1162860, 1162556)
  • Cancer Australia (1143699)
  • Cancer Research UK (C29717/A17263, C29717/A18484, C596/A18076, C596/A20921, A23526, A14276, A25233, A29996)
  • Wellcome Trust Senior Investigator Award (103721/Z/14/Z)
  • Pancreatic Cancer UK Future Research Leaders Fund (FLF2015_04_Glasgow)
  • Scottish Genome Partnership (1175759/2158447)
  • Pancreatic Cancer Research Fund
  • MRC/EPSRC Glasgow Molecular Pathology Node
  • The Howat Foundation
  • Italian Cancer Genome Project–Ministry of University (RBAP10AHJB)
  • Associazione Italiana Ricerca Cancro (12182)
  • FP7 European Community Grant Cam-Pac (602783)
  • Italian Ministry of Health (FIMP-CUP_J33G13000210001)
  • ICGC Ontario Institute for Cancer Research
  • Australian Pancreatic Cancer Genome Initiative
  • Garvin Institute of Medical Research
  • CRUK Glasgow Centre (A25142)
  • Core Services at the Cancer Research UK Beatson Institute (A17196)